鲁克索利提尼布对JAK2 V617F阳性细胞中免疫检查点分子表达的作用
Clinical laboratory
|October 9, 2024
概括
鲁克索利提尼布有效地抑制了增殖,并减少了JAK2 V617F阳性髓增殖性瘤中的免疫检查点分子表达. 这种向疗法抑制了癌细胞和调控性T细胞 (Tregs) 中的编程死亡-1 (PD-1) 和编程死亡配体1 (PD-L1).
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 骨髓增殖性瘤 (MPNs) 的特征是JAK2 V617F突变.
- 免疫检查点分子,如编程死亡-1 (PD-1) 和编程死亡连接体1 (PD-L1) 在MPN病变发生过程中发挥作用.
- 调节性T细胞 (Tregs) 在瘤微环境中参与免疫抑制.
研究的目的:
- 研究ruxolitinib在MPNs中的临床意义.
- 评估鲁克索利提尼布对人类红血红血病 (HEL) 细胞增殖和亡的影响.
- 评估 ruxolitinib 对 HEL 细胞和 MPN 患者 PD-1,PD-L1 和 Tregs 表达的影响.
主要方法:
- 招募了JAK2 V617F阳性MPN患者和健康的志愿者.
- 检测到JAK2 V617F突变,并测量了骨髓中的p-JAK2,PD-1和PD-L1表达.
- 用ruxolitinib治疗HEL细胞并分析了关键分子的细胞活力,mRNA和蛋白质表达.
主要成果:
- 新诊断的MPN患者显示p-JAK2,PD-1和PD-L1的高表达,Tregs增加.
- 鲁克索利提尼布显著抑制了HEL细胞的增殖,这种增殖方式取决于剂量和时间.
- 卢克索利替尼治疗减少了HEL细胞中的p-JAK2,PD-1,PD-L1表达,以及Tregs水平.
结论:
- 鲁克索利提尼布有效地抑制了JAK2信号传递,减少了JAK2V617F阳性细胞中的p-JAK2,PD-1和PD-L1表达.
- 这种向抑制通过调节关键免疫检查点分子和Tregs来抑制MPN进展.
- 鲁克索利提尼布在治疗JAK2 V617F阳性MPN方面显示出显著的临床潜力.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Cytotoxic T Cells-mediated Immune Response
857
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
857


